SMART-SF- Prospective Safety Assessment of the THERMOCOOL® SMARTTOUCH® SF Family of Contact Force Sensing Catheters for the Radiofrequency Ablation Treatment of Drug Refractory Symptomatic PAF 

This is a prospective safety assessment of the study device during radiofrequency (RF) ablation treatment of patients with drug refractory symptomatic atrial fibrillation (SMART-SF).

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure (GENETIC-AF)

This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) (EMANATE)

The purpose of this study is to assess the good and bad effects ("efficacy" and "safety") of apixaban compared with warfarin in people with "AF" in whom an early cardioversion is planned.

A Phase 3, Single-Blind Study to Evaluate the Effect of GS-6615 on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT-3 Syndrome

This study will evaluate the effect of GS-6615 on shortening of the corrected QT interval (QTc), safety, and tolerability in adults with type 3 long QT syndrome (LQT3). During the single-blind treatment period (24 weeks), participants will receive GS-6615 and/or placebo to match GS-6615. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving GS-6615 during an open-label extension phase.

Note: For additional information on any trial please contact the Nurse Coordinator as listed above.